Table 1.
Characteristics of Patients Treated With Stereotactic Radiation for Brain Metastases Secondary to Melanoma or Non-Small Cell Lung Carcinoma
| Melanoma Patients (N = 21) |
Non-Small Cell Lung Carcinoma Patients (N = 21) |
|
|---|---|---|
| Median age at brain metastasis diagnosis, y | 71.4 (25-92) | 67.7 (48-82) |
| RPA status | ||
| 1 | 1 (5%) | 0 |
| 2 | 17 (81%) | 16 (76%) |
| 3 | 3 (14%) | 5 (24%) |
| Metastasis concurrent to melanoma diagnosis | 3 | 11 |
| Metachronous metastasis (No. of patients) | 18 | 10 |
| Median time postdiagnosis, y | 4.8 (1-40) | 2.1 (1-9.5) |
| Metastases (N = 23) | Metastases (N = 30) | |
| Delay between diagnosis and planning imaging, d | 24 (7-70) | 29 (8-107) |
| Delay between planning imaging and first radiation, d | 19 (7-57) | 19 (11-77) |
| Irradiation dose prescription (Gy on isodose 80%) | ||
| -Monofractionated (1 × 20 Gy) | 5 (22%) | 3 (10%) |
| -Trifractionated (3 × 9, 10 or 11 Gy) | 15 (65%) | 25 (84%) |
| -Pentafractionated (5 × 5 Gy) | 3 (13%) | 2 (6%) |
| Healthy brain irradiated volume, PTV, cm3 | 9.65 (2.8-19.7) | 7.7 (1.1-29.8) |
| Follow-up | ||
| Metastasis postradiation control | 20/22 | 22/22 |
| Radiologic necrosis occurrence (N metastasis) | 8/22 (38%) | 8/22 (36%) |
| New metastasis on follow-up (N patients) | 5 (22%) | 6 (29%) |
| Median time follow-up (months) | 12 (1.6-23) | 17 (9-23) |
Abbreviations: PTV, planning target volume; RPA, recursive partitioning analysis.